VolitionRx Limited filed a Certificate of Fourth Amendment to its Restated Certificate of Incorporation, which became effective July 17, 2026, to reduce the number of authorized shares of common stock from 325,000,000 to 150,000,000. The Amendment was approved by stockholders-at-the-Annual Meeting held on July 17, 2024, which also saw the election of seven directors and ratification of auditors. VolitionRx Limited is a healthcare technology company that develops and tests for cancer-related genetic profiles.</div>
